Project Grant R01MH134831

Award Date 7/1/24
Completion Date 4/30/27
Dollars Obligated $818K
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98101, USA
Similar Awards
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $779,842 to The Mclean Hospital Corporation to conduct a multi-center, randomized clinical trial evaluating whether the use of biomarkers can lead to better outcomes for patients experiencing a first episode of psychosis (FEP). The key objectives are to develop a clozapine decision support tool based on three specific biomarkers: a...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $731,452 to the University of Alabama at Birmingham (UAB) to conduct a multi-center, randomized clinical trial. The goal is to develop a "Clozapine Decision Support Tool" to better guide treatment decisions for first-episode psychosis patients. The study will characterize 410 patients using three biomarkers - a functional brain scan, a...
The National Institute of Mental Health (NIMH) awarded a $156,500 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Emory University to identify patients with true treatment failure for major depressive disorder (MDD) who may benefit from earlier referral to alternative treatments like transcranial magnetic stimulation, ketamine, and vagus nerve stimulation. The project aims to use trajectory classification methods to empirically separate partial response from true...
The National Institute of Mental Health (NIMH) awarded a $665,508 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada. The goal of this 5-year project is to develop a clozapine decision support tool that utilizes biomarkers to guide treatment for first-episode psychosis (FEP) patients at risk of poor response to conventional first-line antipsychotics. The project will characterize 410 FEP patients...
This Project Grant award from the National Institute of Mental Health (CFDA 93.242 - Mental Health Research Grants) provides $508,500.00 to New York University School of Medicine to leverage electronic health records, dimensional phenotyping, and whole genome sequencing to build machine learning-based predictive models for four major outcomes in psychosis-related disorders: treatment response, illness severity, medical comorbidities, and diagnostic transitions. The project aims to discover novel...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) totaling $831,180 aims to advance precision psychiatry through a "learning health care system" framework. The award will fund a collaborative effort by the PSYCHEMERGE network to address key barriers to scalability, utility of genomic data, clinical application, and translation to practice in precision psychiatry. Specifically, the project will...
The National Institute of Mental Health (NIMH) awarded a $2,754,722 Cooperative Agreement (UG3MH137656) under the Mental Health Research Grants program (CFDA 93.242) to Weill Medical College of Cornell University. The project aims to develop and test a novel biomarker-guided approach for selecting the most effective treatment for individuals with treatment-resistant depression. This includes optimizing statistical classifiers using machine learning techniques to predict antidepressant...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $1,217,886 to conduct a multi-center, randomized clinical trial to develop a decision support tool for using biomarkers to guide treatment of first-episode psychosis patients. The project, titled "Biomarkers to Enhance Early Schizophrenia Treatment (BEEST)," aims to evaluate whether using three specific biomarkers - a functional brain scan,...
This $812,950 Project Grant awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will fund the "PSYCHEMERGE: ADVANCING PRECISION PSYCHIATRY" research project. The project aims to develop a nationwide federated transfer-learning platform for generalizable and bias-aware algorithms, integrate advanced genomic analysis methods with electronic health record data to uncover novel biology informing precision psychiatry, and...
This Project Grant award of $795,000.00 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will fund a multi-center randomized clinical trial to develop a Clozapine Decision Support Tool for First Episode Psychosis (FEP) patients. The trial aims to evaluate the efficacy of using three biomarkers - a functional brain scan, and genetic tests for weight gain and agranulocytosis risk - to identify FEP patients who may not respond to...

MACHINE LEARNING TO PERSONALIZE ANTIDEPRESSANT TREATMENT - HALF OF PEOPLE STARTING ANTIDEPRESSANT MEDICATION EXPERIENCE NO SIGNIFICANT IMPROVEMENT WITH THE FIRST MEDICATION PRESCRIBED, LEADING EITHER TO DISCOURAGEMENT AND DROPOUT OR MONTHS OF TRIAL-AND-ERROR. MORE ACCURATELY MATCHING INDIVIDUALS WITH SPECIFIC MEDICATIONS COULD SIGNIFICANTLY INCREASE TREATMENT SUCCESS. WHILE SELECTING ANTIDEPRESSANT MEDICATION IS ONE OF THE MOST COMMON CLINICAL DECISIONS IN MENTAL HEALTH AND GENERAL MEDICAL CARE, ACTIONABLE EVIDENCE TO GUIDE THAT DECISION IS REMARKABLY SCARCE. MATCHING PATIENTS WITH SPECIFIC MEDICATIONS REMAINS NO BETTER THAN CHANCE. WE IDENTIFY THREE KEY GAPS IN PREVIOUS RESEARCH TO PERSONALIZE ANTIDEPRESSANT SELECTION. FIRST, PREVIOUS RESEARCH HAS NOT CLEARLY DISTINGUISHED PREDICTING OVERALL PROGNOSIS OR NONSPECIFIC RESPONSE FROM PREDICTING SPECIFIC RESPONSE TO SPECIFIC MEDICATIONS. SECOND, SAMPLE SIZES HAVE TYPICALLY BEEN INADEQUATE TO ACCURATELY DETECT DIFFERENTIAL TREATMENT RESPONSE. THIRD, PREVIOUS RESEARCH HAS FOCUSED ON RESPONSE TO A SINGLE EPISODE OF TREATMENT, AND THAT IS TOO "NOISY" A CLINICAL PHENOTYPE TO SUPPORT IDENTIFICATION OF USEFUL ENDOPHENOTYPES. WE PROPOSE TO ADDRESS THESE LIMITATIONS USING DATA RESOURCES, INFORMATICS TOOLS, AND ANALYTIC METHODS DEVELOPED BY THE NIMH-FUNDED MENTAL HEALTH RESEARCH NETWORK (MHRN). RECORDS DATABASES INCLUDE COMPREHENSIVE AND HARMONIZED DATA CONCERNING SOCIODEMOGRAPHIC CHARACTERISTICS, PAST MENTAL HEALTH DIAGNOSES AND TREATMENTS, COMORBID MENTAL HEALTH OR SUBSTANCE USE DISORDERS, CONCOMITANT TREATMENTS, DOSE AND DURATION OF ANTIDEPRESSANT EXPOSURE, AND STRUCTURED ASSESSMENT OF DEPRESSION SYMPTOMS AT BASELINE AND FOLLOW-UP. WE WILL ASSEMBLE A DATABASE INCLUDING OVER 500,000 ANTIDEPRESSANT TREATMENT EPISODES FOR OVER 200,000 PATIENTS TREATED SINCE 2010 IN ORDER TO: 1) RIGOROUSLY TEST CORE ASSUMPTIONS OF PREVIOUS RESEARCH AND TREATMENT GUIDELINES - HETEROGENEITY-OF- TREATMENT-EFFECTS ANALYSES WILL EVALUATE TWO COMMON BELIEFS REGARDING ANTIDEPRESSANT RESPONSE: A. FAVORABLE OR UNFAVORABLE PRIOR RESPONSE TO A SINGLE MEDICATION PREDICTS SUBSEQUENT RESPONSE B. PRIOR RESPONSE TO A MEDICATION IN A SPECIFIC CLASS PREDICTS SUBSEQUENT RESPONSE TO THAT CLASS 2) IDENTIFY AND VALIDATE DECISION RULES TO INFORM SELECTION OF ANTIDEPRESSANT TREATMENT BASED ON PATTERNS OF PRIOR TREATMENT RESPONSE - ANALYSES WILL USE MACHINE LEARNING METHODS (DYNAMIC WEIGHTED ORDINARY LEAST SQUARES REGRESSION) TO IDENTIFY AND VALIDATE PRACTICAL DECISION RULES FOR CLINICAL PRACTICE. 3) IDENTIFY VALID TREATMENT RESPONSE PHENOTYPES TO ENABLE FUTURE RESEARCH REGARDING GENOMIC- OR BIOMARKER-GUIDED PERSONALIZATION - PRIMARY ANALYSES WILL USE K-MEANS CLUSTERING TO IDENTIFY PATTERNS OF RESPONSE ACROSS MEDICATIONS AND MEDICATION CLASSES. ADDITIONAL ANALYSES WILL EXPLORE CLINICAL CHARACTERISTICS THAT DISTINGUISH RESPONSE PHENOTYPES AS WELL AS ORDER EFFECTS. FINDINGS WILL INFORM A NEXT GENERATION OF RESEARCH REGARDING GENETIC- AND BIOMARKER-GUIDED ANTIDEPRESSANT TREATMENT.

Posted 6/27/24, 12:00 AM